Clinical Cohort of Lymphoma Patients in Malawi

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-11-30

Study Completion Date

2030-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry study is intended to establish a large prospective longitudinal clinical cohort of lymphoma patients in Malawi, as such data is currently lacking from sub-Saharan Africa. The investigators will perform core biopsies on at least 800 consecutively enrolled patients with suspected lymphoma for accurate histopathologic characterization. The investigators will systematically collect relevant clinical and laboratory data, and longitudinally follow those with confirmed hematologic malignancies receiving treatment according to local standards of care to assess outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi

NCT03160183

Kaposi Sarcoma HIV

COMPLETED

Biology Studies of Hematologic Cancers

NCT00923442

Acute Lymphoblastic Leukemia Myelodysplastic Syndrome (MDS) Non-Hodgkins Lymphoma +2 more

ENROLLING_BY_INVITATION

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014

Non-Hodgkin's Lymphoma Hodgkin's Disease Leukemia, Lymphocytic, Chronic +1 more

RECRUITING

Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma

NCT04062877

Lymphoma

COMPLETED

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

NCT04468841

Follicular Lymphoma

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational cohort registry study of at least 800 patients with suspected lymphoma in Malawi. The primary purpose of this study is to develop a large prospective longitudinal lymphoma cohort at Kamuzu Central Hospital (KCH). Subjects with confirmed hematologic malignancies treated according to local standards of care will be actively followed for 2 years after diagnosis to assess clinical outcomes. After 2 years, if subjects are well, they will be discharged from clinic if they desire and contacted via telephone every 6 months for 5 years after lymphoma diagnosis simply to assess vital status. Subjects who wish to continue clinic follow-up after 2 years will be seen every 6 months until 5 years after lymphoma diagnosis. Those who are unwell after 2 years and continuing to receive active treatment will continue follow-up in clinic with all treatment details recorded.

All study laboratories and procedures which are being performed are consistent with international standards of care. Even without study implementation, all procedures may be undergone by patients at KCH, and there is no 'new' intervention being provided by the study which is currently absent in Malawi. However, current clinical and laboratory assessments of lymphoma patients at KCH over time are typically highly inconsistent and incomplete by international standards, as a result of extreme scarcity of resources and personnel. It is therefore hoped that the study will provide greater standardization and uniformity in the longitudinal characterization of patients with lymphoma at KCH, and allow data collected to be used for clinical as well as research purposes, as such data from sub-Saharan Africa are lacking and can be tremendously informative.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Hematologic Malignancies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lymphoma

Suspected lymphoma with confirmed hematologic malignancies treated under local conditions

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Referred to Kamuzu Central Hospital (KCH) with clinically suspected lymphoma based on clinical impression of referring providers Age \>5 years, or ≤5 years only if lymphoma has already been pathologically confirmed.
* No prior or concurrent histologically confirmed cancer diagnosis or receipt of cancer treatment.
* Residence \<200 kilometers from KCH. Able to understand and comply with study procedures for the entire length of the study, with assistance of parent or guardian as applicable.
* Subject (or parent or guardian as applicable) able to understand and provide written consent in English or Chichewa.
* Informed consent reviewed and signed by patient, or for pediatric patients, from parent or guardian.

* Patients may consent to participation in the study but refuse directed genomic analysis of their lymphoma specimens.

Minimum Eligible Age

0 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No